Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II open label Biomarker Research Study off PF-03084014 in non-metastatic
triple-negative breast cancer patients with residual disease (cHEmoresistant) after
completion of standard neoadjuvant chemotherapy.